News - Ambergen Inc.

March 2018/by Kenneth Rothschild

AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing

February 2018/by Kenneth Rothschild

Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™)

January 2018/by Kenneth Rothschild

AmberGen awarded $2 million, 2-year Phase IIb SBIR grant from NIH-NIAID to further develop its PC-PURE™-assisted, multiplex, in vitro AllerBead™ assay which uses finger-stick blood for the highly multiplex quantification of allergen-specific IgE

February 2017/by Kenneth Rothschild

AmberGen acquires a new state-of-the-art Bruker rapifleX™ MALDI mass spectrometer for ultra-fast and high resolution mass spectrometry imaging of its Bead-AMS™ proteomic bead-arrays

January 2017/by Kenneth Rothschild

Dr. Gargey Yagnik joins AmberGen as Program Coordinator for Mass Spectrometry. In his previous position as a postdoctoral researcher at Sanofi Genzyme he developed new methods for MALDI-MSI tissue imaging. He received his Ph.D. from Iowa State University in analytical chemistry.

December 2016/by Kenneth Rothschild

AmberGen awarded two US Patents (9,513,285 and 9,523,680) providing broad coverage for its Bead-AMS™ technologies

December 2016/by Kenneth Rothschild

AmberGen Founder and Chairman of the Board, Dr. Ken Rothschild, was elected as a Fellow of the National Academy of Inventors (NAI). The election as an NAI Fellow honors contributions from inventors who have made a tangible impact on quality of life, economic development and welfare of society.

November 2016/by Kenneth Rothschild

AmberGen pioneers new Bead Array Mass Spectrometry Technology (Bead-AMS™) and is awarded 3 U.S. patents providing broad coverage

September 2016/by Kenneth Rothschild

AmberGen awarded 3-year Phase II SBIR grant from NIH-NIGMS to develop Bead-AMS™ for screening on- and off-target drug binding on a proteome-wide scale

July 2016/by Kenneth Rothschild

AmberGen awarded Phase I SBIR grant from NIH-NCI IMAT program to develop PC-PURE™ for the detection of serological ovarian cancer biomarkers

May 2016/by Kenneth Rothschild

Paper published in Nature’s Scientific Reports “Proteome-wide drug screening using mass spectrometric imaging of bead-arrays” describing drug-discovery application of Bead-AMS™ including detection of on- and off-target drug binding

May 2016/by Kenneth Rothschild

AmberGen receives US Patent 9,334,530 for its Bead-AMS™ technology describing synchronization of mass spectrometric and fluorescence images of mass-tagged bead arrays

July 2015/by Kenneth Rothschild

John Gillespie, former Director of R&D for 3 Johnson & Johnson businesses including their multi-billion dollar Ethicon Products business, joins AmberGen as VP of Product and Business Development

February 2015/by Kenneth Rothschild

Paper published in Liver International “Anti-Kelch-like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis” resulting from a collaboration between AmberGen, INOVA Diagnostics and MGH

January 2015/by Kenneth Rothschild

AmberGen receives US Patent 8,932,879 for its pioneering PC-PRINT™ technology

December 2014/by Kenneth Rothschild

AmberGen receives US Patent 8,906,700 providing broad coverage on PC-PURE™ technology for biomarker isolation and use in highly sensitive and quantitative assays

October 2014/by Kenneth Rothschild

AmberGen and Massachusetts General Hospital (MGH) are awarded US Patent 8,852,956 for two new diagnostic autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC)

July 2014/by Kenneth Rothschild

AmberGen awarded 2-year Phase II SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions

February 2014/by Kenneth Rothschild

AmberGen awarded 3-year Phase II SBIR grant from NIH-NIAID for development of a multiplex in vitro pediatric allergy test

January 2014/by Kenneth Rothschild

Paper published in Rapid Communications in Mass Spectrometry “Correlated matrix-assisted laser desorption/ionization mass spectrometry and fluorescent imaging of photocleavable peptide-coded random bead-arrays” describing proteomic applications of Bead-AMS™

December 2013/by Kenneth Rothschild

Paper published in Journal of Immunological Methods “Multiplexed VeraCode bead-based serological immunoassay for colorectal cancer” detailing the development of a serological assay for colorectal cancer biomarkers based on the novel use of the VeraCode™ multiplex bead assay system

August 2013/by Kenneth Rothschild

AmberGen receives US Patent 8,507,648 for novel method of detecting protease activity using mass spectrometry

July 2013/by Kenneth Rothschild

AmberGen receives US Patent 8,486,634 for novel method of detecting DNA methylation using solid-phase PCR

July 2013/by Kenneth Rothschild

AmberGen receives US Patent 8,481,263 for creating self-assembled bead-protein libraries by solid-phase PCR and nascent protein expression

October 2012/by Kenneth Rothschild

AmberGen receives US Patent 8,288,098 for a novel method of DNA sequencing using nucleotides having cleavable detectable labels

October 2012/by Kenneth Rothschild

AmberGen receives US Patent 8,278,045 for detecting chain truncation mutations which cause breast and colorectal cancer

September 2012/by Kenneth Rothschild

AmberGen awarded Phase I SBIR grant for the application of photocleavable bead technology to glycomics

April 2012/by Kenneth Rothschild

AmberGen receives US Patent 8,148,062 for detecting disease causing genetic mutations such as breast and colorectal cancer using affinity tags in translated nascent proteins

April 2012/by Kenneth Rothschild

AmberGen awarded 3-year Phase II SBIR grant for discovery of tumor autoantigen biomarkers using Bead-AMS™ proteomic array technology

March 2012/by Kenneth Rothschild

AmberGen and Massachusetts General Hospital license the use of two novel autoantigen biomarkers for autoimmune liver disease to INOVA Diagnostics

March 2012/by Kenneth Rothschild

AmberGen awarded Phase I SBIR grant for development of a multiplex in vitro pediatric allergy test

February 2012/by Kenneth Rothschild

AmberGen receives US Patent 8,114,587 for analyzing DNA mutations in fecal samples for colorectal cancer detection

November 2011/by Kenneth Rothschild

Agreement between AmberGen and SomaLogic® enables use of photocleavable reagent in SOMAmer® technology used to discover new biomarkers

September 2011/by Kenneth Rothschild

AmberGen awarded Phase I SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions

March 2011/by Kenneth Rothschild

AmberGen receives US Patent 7,897,335 for electrophoresis-free methods of high sensitivity detection of chain truncation mutations using tagged translated nascent proteins

February 2011/by Kenneth Rothschild

AmberGen wins Illumina’s VeraCode™ Assay Design Challenge for development of a multiplex colorectal cancer diagnostic

January 2011/by Kenneth Rothschild

Promega distributes AmberGen’s fluorescent tRNA based protein engineering technology

January 2011/by Kenneth Rothschild

Thermo-Fisher sells AmberGen’s PC-Biotin-NHS reagent

January 2011/by Kenneth Rothschild

Glen Research distributes AmberGen’s Photocleavable Phosphoramidite DNA-labeling reagents

January 2011/by Kenneth Rothschild

Menu

Get in Touch

Recent News

Recent Posts